For its next pare-down move, Pfizer weighs sale of Hospira pump business: Bloomberg

Emily Wasserman

has been contemplating a large-scale breakup for a while, with analysts expecting the company to split off its established drugs once it integrates assets from last year's $ 15 billion buy. Now, with its purchase under its belt, the company is thinking about selling off the pumps and devices business it picked up through the deal, potentially laying the foundation for a spinoff.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS